SUPPLEMENTARY TABLES

Supplementary Table 1. Descriptive statistics for ten Latin American and Caribbean countries.

Country	Population of children <5 years of age in 2010 (millions)	Product, schedule, and year of universal introduction	Vaccine coverage (% with at least 3 doses) ^a	Pre-PCV period	Post-PCV period	Average annual reported incidence of all-cause pneumonia deaths among 2-59 months of age per 100,000 in the pre-PCV period	Average annual reported incidence of all-cause pneumonia deaths among 2-59 months of age per 100,000 in the post-PCV period
Argentina	3.4	PCV13 (2+1) in Jan-2012	85.3	Jan-2005 to Dec-2011	Jan-2012 to Dec-2015	7.8	5.6
Brazil	15.2	PCV10 (3+1) in Mar-2010 PCV10 (2+1) in Jan-2017	81.7	Jan-2005 to Feb-2010	Mar-2010 to Dec-2015	15.4	12.3
Colombia	4.5	PCV10 (2+1) in Nov-2011	84	Jan-2005 to Oct-2011	Nov-2011 to Dec-2015	14.2	9.6
Dominican Republic	1.1	PCV13 (2+1) in Sep-2013	NA^b	Jan-2005 to Aug-2013	Sep-2013 to Dec-2015	8.9	4.6
Ecuador	1.6	PCV7 in Aug- 2010 PCV10 (2+1) in Feb-2011 PCV10 (3+0) in Feb-2014	94.7	Jan-2005 to Jul-2010	Aug-2010 to Dec-2016	27.7	17.8
Guyana	0.1	PCV13 (3+0) in Jan-2011	90	Jan-2000 to Dec-2010	Jan-2011 to Dec-2013	25.2	19.6
Honduras	1.0	PCV13 (3+0) in Jan-2011	88	Jan-2007 to Dec-2010	Jan-2011 to Dec-2016	24.7	26.6
Mexico	11.6	PCV7 (2+1) in Feb-2008 PCV13 (2+1) in Feb- 2011 ^c	92	Jan-2000 to Jan-2008	Feb-2008 to Dec-2016	18.8	12.3
Nicaragua	0.7	PCV13 (3+0) in Jan-2012	91	Jan-2005 to Dec-2011	Jan-2012 to Dec-2015	27.3	26.4
Peru	2.9	PCV7 (2+1) in Aug-2009 PCV10 (2+1) in Dec-2011	82	Jan-2005 to Jul-2009	Aug-2009 to Dec-2014	29.6	21.0

Population aged under 5 was obtained from the Human Development Reports from the United Nations Development Programme (http://hdr.undp.org/en/content/population-aged-under-5-millions).

Abbreviations: PCV, pneumococcal conjugate vaccine; CrI, credible interval.

^a National-level coverage one year after PCV was introduced.
^b The Dominican Republic prioritized administration of two doses due to a short-term shortage of vaccine supply, so had low uptake of three doses. The second dose coverage ranged from 49·5-92·2% at the subnational level.

^c Phased introduction starting in 2006 and switch in schedule.